Read on Twitter
When I write these, it is IMPARITIVE to read all the way through
The following thread is why I like $KTOV
Catalyst within this week
Close to technical breakout
Has 6 catalyst by end of the year… literally one a month lol
The following thread is why I like $KTOV
Catalyst within this week
Close to technical breakout
Has 6 catalyst by end of the year… literally one a month lol
The big picture:
Ktov is massively under valued at a 30 million market cap
Stock has been beat down close too 78% in the last year because of dilution
Ktov has over 5 material Catalyst from now till EOY
Ktov is massively under valued at a 30 million market cap
Stock has been beat down close too 78% in the last year because of dilution
Ktov has over 5 material Catalyst from now till EOY
FOLLOW THE MONEY
In the last 6 weeks 3 major institutions have acquired or increased positions up to 23%
In the last 6 weeks 3 major institutions have acquired or increased positions up to 23%
Now I am not worried about an offering (Still do not have a crystal ball)
They completed a $10 million offering on Friday, at the current burn rate that should last them for the foreseeable future.
They completed a $10 million offering on Friday, at the current burn rate that should last them for the foreseeable future.
NOW we get into the GOOOOD SH***T
The connecting of the dots
KTOV Is about to launch ConSensi which is able to possibly treat up to 100 MILLION patients
MOST IMPORTANT SENTENCE:
The connecting of the dots
KTOV Is about to launch ConSensi which is able to possibly treat up to 100 MILLION patients
MOST IMPORTANT SENTENCE:
“ConsensiTM is under patent protection in the U.S. until 2030 and will be the only NSAID whose labeling indicates a reduction of blood pressure and consequent risk reduction of heart attack, stroke and death.”
PATENT for next 10 years
AND THE ONLY NSAID
PATENT for next 10 years
AND THE ONLY NSAID
In addition,
For patients, Consensi™ treats two conditions simultaneously, thereby increasing convenience (one pill instead of two) and may offer lower co-pays. The therapy may contribute to improved patient compliance and improved patient health,
For patients, Consensi™ treats two conditions simultaneously, thereby increasing convenience (one pill instead of two) and may offer lower co-pays. The therapy may contribute to improved patient compliance and improved patient health,
thereby lowering overall health care costs.
KTOV sold the commercialization to coeptis… they just sit back and BANK
“Coeptis will commercialize Kitov’s combination drug, Consensi™, intended to simultaneously treat osteoarthritis pain and hypertension.”
KTOV sold the commercialization to coeptis… they just sit back and BANK
“Coeptis will commercialize Kitov’s combination drug, Consensi™, intended to simultaneously treat osteoarthritis pain and hypertension.”
